|
Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders
NU 2025-113 (NU 2016-137, NU 2018-176, NU 2019-179, NU 2023-007, NU 2024-250, NU 2025-038)
INVENTORS
Richard Silverman (Weinberg College of Arts and Sciences, Department of Chemistry)
SHORT DESCRIPTION
Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression...
Published: 4/1/2026
|
Updated: 4/1/2026
|
Inventor(s):
Keywords(s): ALS - Amyotrophic Lateral Sclerosis, AUTM26C1, BIAUTM1, Cancer/Oncology, Cardiology and Cardiovascular disease, Immunodeficiency, Immunology, Immunotherapy, Melanoma, Neurodegenerative disease, Neuroinflammation, nNOS, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
The use of complex or fusion protein of soluble MIC (Smic) and antibody to treat MIC-negative cancer
NU 2019-146
INVENTORS
Jennifer Wu*
SHORT DESCRIPTION
A fusion protein complex comprising soluble MIC and a non-blocking sMIC-neutralizing antibody that effectively activates CD8 T cells for the treatment of MIC-negative cancer.
BACKGROUND
Effective T cell co-stimulation is critical for durable tumor control, yet many current immunotherapies...
Published: 4/9/2026
|
Updated: 12/3/2025
|
Inventor(s):
Keywords(s): Antibody, Biologic, Cancer/Oncology, Immunotherapy, Infectious disease, Research tool, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Engineered B-cell Therapy for Cancer Treatment
NU 2022-218
INVENTORS
Catalina Lee Chang*
Maciej Lesniak*
SHORT DESCRIPTION
Engineered B cells with reduced expression of key immune checkpoint proteins designed to boost cancer immunotherapy efficacy.
BACKGROUND
Immunotherapy has transformed cancer treatment; however, its application to brain tumors remains limited by the immunosuppressive...
Published: 4/8/2026
|
Updated: 12/3/2025
|
Inventor(s):
Keywords(s): Cancer/Oncology, Cell therapy, Immunotherapy, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Compositions and Methods for the Treatment of Intestinal Inflammation
NU 2021-252
INVENTORS
Matthew Bury
Muthukumar Gunasekaran
Sunjay Kaushal
Arun Sharma*
Tiffany Sharma
BACKGROUND
Crohn’s Disease (CD) is partly caused by a highly pro-inflammatory lesion microenvironment which subsequently causes numerous clinical complications. Northwestern University scientists have developed a method to control...
Published: 3/17/2026
|
Updated: 2/25/2025
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cell therapy, IBD - Inflammatory bowel disease, Immunotherapy, Infectious disease, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Anti-CD73 Monoclonal Antibody for Enhanced Cancer Immunotherapy
NU 2020-207
INVENTORS
Bin Zhang*
Siqi Chen
Jie Fan
SHORT DESCRIPTION
This invention comprises novel anti-CD73 monoclonal antibody compositions that recognize and inhibit mouse and human CD73.
BACKGROUND
CD73, an ecto-enzyme associated with adenosine metabolism, is an emerging immune checkpoint that promotes tumor progression by suppressing...
Published: 12/11/2025
|
Updated: 1/30/2025
|
Inventor(s):
Keywords(s): Brain cancer, Breast cancer, Cancer/Oncology, Colon cancer, Gastric cancer, Immunotherapy, Lung cancer, Ovarian cancer, Pancreatic cancer, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
CAR T Cells Armored with IL15 for Treating Glioblastoma
NU 2022-074
INVENTORS
Irina V. Balyasnikova*
BACKGROUND
Glioblastoma is a devastating brain cancer for which no effective treatment exists, leading to short patient survival. Although investigations are underway to explore chimeric antigen receptor T (CAR-T) cells as glioblastoma therapy, the immunosuppressive tumor microenvironment (TME)...
Published: 4/9/2026
|
Updated: 10/17/2024
|
Inventor(s):
Keywords(s): Brain cancer, Cancer/Oncology, Cell therapy, Immunology, Immunotherapy, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
New Lipiodol Formulation for Treating Hepatocellular Carcinoma with Transarterial Chemoimmunoembolization
NU 2021-148
INVENTORS
Dong Hyun Kim*
Heegon Kim
SHORT DESCRIPTION
A new Lipiodol formulation designed to improve the efficacy and safety of transarterial chemoembolization in combination with immunotherapy.
BACKGROUND
Transarterial chemoembolization...
Published: 12/11/2025
|
Updated: 9/4/2024
|
Inventor(s):
Keywords(s): Cancer/Oncology, Drug delivery, Immunotherapy, Liver cancer, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Methods and Compounds that block the release of enveloped viruses from cells
NU 2019-084
INVENTORS
Jonathan Leis*
Chi-Hao Luan
SHORT DESCRIPTION
Antiviral agents targeting a broad range of enveloped viruses for pan-viral therapeutics
BACKGROUND
To date, there are very few shared mechanisms identified between families of shared viruses. As such, there is minimal development of a broad-spectrum antiviral. Enveloped viruses...
Published: 11/6/2025
|
Updated: 6/2/2023
|
Inventor(s):
Keywords(s): Immunology, Immunotherapy, Infectious disease, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Immuno-Ablation Agent for Combination Therapy Against Solid Tumors
NU 2022-058
INVENTORS
Dong Hyun Kim*
Kijung Kwak
Bo Yu
SHORT DESCRIPTION
A method of co-delivering immune modulating agents during ethanol ablation of solid tumors
BACKGROUND
Ethanol ablation therapy is a simple and inexpensive method commonly employed to shrink solid tumors. Like other tumor ablation techniques, such as radiofrequency ablation,...
Published: 11/6/2025
|
Updated: 6/22/2022
|
Inventor(s):
Keywords(s): Cancer/Oncology, Drug delivery, Immunology, Immunotherapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
IDO-PROTACs for Improving the Anti-Cancer Immune Response
NU 2020-137
INVENTORS
Derek Wainwright*
Gary Schiltz
SHORT DESCRIPTION
IDO-PROTAC that target immunosuppressive IDO activity via degradation
ABSTRACT
The median survival of primary GBM patients following aggressive surgical intervention, radiotherapy, chemotherapy, and tumor treating fields (TTF) is only ~14-16 months. Indoleamine 2,3-dioxygenase...
Published: 3/3/2026
|
Updated: 5/27/2022
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Brain cancer, Cancer/Oncology, Colon cancer, Endometrial cancer, Immunotherapy, Pancreatic cancer, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|